139 related articles for article (PubMed ID: 1551173)
1. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
Olver IN; Webster LK; Bishop JF; Stokes KH
Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
de Forni M; Chabot GG; Armand JP; Gouyette A; Klink-Alak M; Recondo G
Cancer Chemother Pharmacol; 1995; 35(3):219-24. PubMed ID: 7805180
[TBL] [Abstract][Full Text] [Related]
3. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.
Pratt CB; Relling MV; Meyer WH; Douglass EC; Kellie SJ; Avery L
Am J Clin Oncol; 1991 Dec; 14(6):483-6. PubMed ID: 1957836
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
7. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
8. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
Stratford MR; Rustin GJ; Dennis MF; Watfa RR; Howells N; O'Reilly SM
Br J Cancer; 1993 Jun; 67(6):1351-5. PubMed ID: 8512820
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.
Chabot GG; Bissery MC; Corbett TH; Rutkowski K; Baker LH
Cancer Chemother Pharmacol; 1989; 24(1):15-22. PubMed ID: 2597279
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent pharmacokinetics of flavone acetic acid in mice.
Damia G; Zanette ML; Rossi C; Mandelli R; Ferrari A; D'Incalci M
Cancer Chemother Pharmacol; 1988; 22(1):47-50. PubMed ID: 3396145
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of flavone acetic acid.
Kerr DJ; Kaye SB; Cassidy J; Bradley C; Rankin EM; Adams L; Setanoians A; Young T; Forrest G; Soukop M
Cancer Res; 1987 Dec; 47(24 Pt 1):6776-81. PubMed ID: 3677106
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
14. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).
Weiss RB; Greene RF; Knight RD; Collins JM; Pelosi JJ; Sulkes A; Curt GA
Cancer Res; 1988 Oct; 48(20):5878-82. PubMed ID: 3167843
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).
Dodion PF; Abrams J; Gérard B; Crespeigne N; Peeters B; Van Berchem C; Kenis Y
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):837-42. PubMed ID: 3653200
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM
Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
